Correction: Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex

Cindy K. Miranti; Sara Moore; Yongeun Kim; Venkateshwar Reddy Chappeta; Kui Wu; Biswanath De; Vijay Gokhale; Laurence H. Hurley; Elsa M. Reyes-Reyes

doi:10.18632/oncotarget.27661

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex

PDF | How to cite

Oncotarget. 2020; 11:2586-2586. https://doi.org/10.18632/oncotarget.27661

Metrics: PDF 1120 views | ?

Cindy K. Miranti^1,2, Sara Moore³, Yongeun Kim⁴, Venkateshwar Reddy Chappeta⁴, Kui Wu⁴, Biswanath De⁴, Vijay Gokhale⁵, Laurence H. Hurley^1,4,5 and Elsa M. Reyes-Reyes^1,2,3

¹ University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
² Department of Cellular and Molecular Medicine, Tucson, AZ 85724, USA
³ University of Arizona College of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Tucson, AZ 85724, USA
⁴ College of Pharmacy, University of Arizona, Tucson, AZ 85724, USA
⁵ BIO5 Institute, University of Arizona, Tucson, AZ 85724, USA

Published: June 30, 2020

This article has been corrected: The Acknowledgements section has been updated as follows:

ACKNOWLEDGMENTS

These studies were supported by funds from IRG-16-124-37 from the America Cancer Society and University of Arizona Career Development Award to EMRR and by NIH award R01CA177585 to L.H.H.

Original article: Oncotarget. 2020; 11:1758–1776. DOI: https://doi.org/10.18632/oncotarget.27589.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27661

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex